Search

Big bang nucleosynthesis (BBN) is the standard model theory for the production of light nuclides during the early stages of the universe, taking place about 20 minutes after the big bang. Deuterium production, in particular, is highly sensitive to the primordial baryon density and the number of neutrino species, and its abundance serves as a sensitive test for the conditions in the early universe. The comparison of observed deuterium abundances with predicted ones requires reliable knowledge of the relevant thermonuclear reaction rates and their corresponding uncertainties. Recent observations reported the primordial deuterium abundance with percent accuracy, but some theoretical predictions based on BBN are in tension with the measured values because of uncertainties in the cross section of the deuterium-burning reactions. In this work, we analyze the S-factor of the D(p,γ)3He reaction using a hierarchical Bayesian model. We take into account the results of 11 experiments, spanning the period of 1955-2021, more than any other study. We also present results for two different fitting functions, a two-parameter function based on microscopic nuclear theory and a four-parameter polynomial. Our recommended reaction rates have a 2.2% uncertainty at 0.8 GK, which is the temperature most important for deuterium BBN. Differences between our rates and previous results are discussed.

The prevalence of Celiac disease in the general population is approximately 1% and remains undiagnosed in a significant proportion of individuals. Its clinical presentation includes the classical malabsorption syndrome, unspecific and extra-intestinal manifestations, and silent celiac disease. The serologic diagnosis has an elevated sensitivity and specificity and, at least in adult population, it must be confirmed by biopsy in every case. Diagnosis in subjects already on gluten free diet includes HLA typing and gluten challenge with posterior serologic and histologic evaluation. The core of the treatment is the gluten free diet, which must be supervised by an expert nutritionist. Monitoring must be performed with serology beginning at 3-6 months, and with histology two years after the diagnosis, unless the clinical response is poor. Poor disease control is associated with complications such as lymphoma and small bowel adenocarcinoma. In the future, it is likely that new pharmacologic therapies will be available for the management of celiac disease.

The prevalence of Celiac disease in the general population is approximately 1% and remains undiagnosed in a significant proportion of individuals. Its clinical presentation includes the classical malabsorption syndrome, unspecific and extra-intestinal manifestations, and silent celiac disease. The serologic diagnosis has an elevated sensitivity and specificity and, at least in adult population, it must be confirmed by biopsy in every case. Diagnosis in subjects already on gluten free diet includes HLA typing and gluten challenge with posterior serologic and histologic evaluation. The core of the treatment is the gluten free diet, which must be supervised by an expert nutritionist. Monitoring must be performed with serology beginning at 3-6 months, and with histology two years after the diagnosis, unless the clinical response is poor. Poor disease control is associated with complications such as lymphoma and small bowel adenocarcinoma. In the future, it is likely that new pharmacologic therapies will be available for the management of celiac disease.

The prevalence of Celiac disease in the general population is approximately 1% and remains undiagnosed in a significant proportion of individuals. Its clinical presentation includes the classical malabsorption syndrome, unspecific and extra-intestinal manifestations, and silent celiac disease. The serologic diagnosis has an elevated sensitivity and specificity and, at least in adult population, it must be confirmed by biopsy in every case. Diagnosis in subjects already on gluten free diet includes HLA typing and gluten challenge with posterior serologic and histologic evaluation. The core of the treatment is the gluten free diet, which must be supervised by an expert nutritionist. Monitoring must be performed with serology beginning at 3-6 months, and with histology two years after the diagnosis, unless the clinical response is poor. Poor disease control is associated with complications such as lymphoma and small bowel adenocarcinoma. In the future, it is likely that new pharmacologic therapies will be available for the management of celiac disease.